euro adhoc: Dr. Hönle AG / Financial Figures/Balance Sheet / Hönle presents figures for the first quarter

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

25.02.2009

The economic situation deteriorated noticeably in the first quarter
of the 2008/2009 financial year. All regions and many industries are
affected by this development and new orders declined significantly in
the printing industry, in particular. Hönle was also not exempted
from this negative economic development. Sales revenues of the Hönle
Group increased by 75.1 % to TEUR 12,751 in the first quarter of the
financial year in comparison with the previous year as a result of
acquisitions but declined by 19.6 % in comparison with the previous
year´s quarter. Earnings before interest and tax (EBIT) dropped from
TEUR 1,381 in the previous year to TEUR -592 in the first quarter of
the current financial year. Earnings before tax (EBT) declined from
TEUR 1,562 to TEUR -594 and the Group´s result decreased from TEUR
1,147 to TEUR -580. Earnings per share dropped from EUR 0.20 to EUR
-0.11.

Liquid assets, securities and own shares amount to TEUR 10,824. The
equity capital ratio is 67.4 %.

Outlook: The restrained investment behaviour, which can be observed
in many sectors, will also impact on Hönle Group´s business
development. However, at present it is almost impossible to forecast
the extent and duration of the restrained investing behaviour, in
particular in the printing industry. In February, the Hönle Group
further extended short-time working in order to adjust manufacturing
capacities to the decline in incoming orders. At present, about 35 %
of the workforce is affected by short-time working.

Following the acquisition of several companies, integrating the new
companies into the Hönle Group will be given priority in the new
financial year. The main objective is to save costs by expanding the
output chain and by centralising certain functions such as joint
purchasing activities. The cost reduction program includes short-term
as well as long-term measures. Manufacture of the Eltosch systems,
which to date has been outsourced to external suppliers, will be
transferred to Dr. Hönle AG in the course of this financial year.
Production will then be combined and Eltosch und Hönle systems will
be produced at one joint site which is both efficient and cost
saving. Panacol and Wellomer will move to new company premises which
they will use jointly. The production processes of these companies
will also be combined to enable more efficient and cost-saving
manufacture. Moreover, R&D capacities can be utilised more
efficiently.

Savings in Purchasing will improve the cost situation. Materials
procurement in plant engineering and in the adhesives segment will be
centralised within the Hönle Group, which will optimise purchasing
conditions.

Overall, the Board of Management is convinced that UV technology will
continue to grow in popularity despite the present economic
situation. Due to the advantages of UV technology in comparison with
conventional drying and curing processes, its popularity and use in
new fields will increase. Following the corporate acquisitions, the
Hönle Group has positioned itself strongly in a very interesting
market environment: It is now the second largest systems supplier
worldwide in the market for industrial UV technology. Hönle is thus
well equipped to overcome a period of economic weakness and to emerge
stronger from the financial crisis. The restructuring measures
initiated will see Hönle better positioned than ever for future
profitable growth after the presently restrained investing behaviour
has come to an end.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Dr. Hönle AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Hönle AG, Peter Weinert, Lochhamer Schlag 1, 82166 Gräfelfing/Munich, Tel.:
089-85608-173, Fax: 089-85608-148, ir@hoenle.de, www.hoenle.de

Branche: Instrument Engineering
ISIN: DE0005157101
WKN: 515710
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade